# Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer

> **NCT00003070** · PHASE3 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 13 (actual)

## Conditions studied

- Cardiac Toxicity
- Unspecified Childhood Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** enalapril maleate
- **PROCEDURE:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT00003070
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-09
- **Primary completion:** 2003-07
- **Final completion:** 2007-03
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2014-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003070, "Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00003070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*